Stock Events

Stock Events

Zealand Pharma A/S. 

€40.42
132
+€0.61+1.53% Today

Statistics

Day High
41.05
Day Low
40.42
52W High
73.8
52W Low
32
Volume
600
Avg. Volume
-
Mkt Cap
2.89B
P/E Ratio
3.35
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.37
4.83
11.03
17.22
Expected EPS
-1.3651088532
Actual EPS
N/A

Financials

70.05%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.47BRevenue
1.73BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 22Z.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap182.6B
Novo Nordisk is a leading global healthcare company that competes with Zealand Pharma in the diabetes and obesity drug markets, areas where Zealand Pharma also operates.
Sanofi
SNY
Mkt Cap112.08B
Sanofi is a large pharmaceutical company that competes with Zealand Pharma in the development of treatments for diabetes and cardiovascular diseases.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly is a major player in the pharmaceutical industry, competing with Zealand Pharma in the diabetes care sector, particularly in the development of GLP-1 receptor agonists.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca competes with Zealand Pharma in several areas, including the development of new treatments for diabetes and other metabolic disorders.
Merck
MRK
Mkt Cap276.38B
Merck is a global healthcare company that competes with Zealand Pharma in the diabetes sector, particularly in the development of novel therapeutics.
Medicinova
MNOV
Mkt Cap67.43M
MediciNova is involved in the development of novel therapeutics for diseases with unmet medical needs, overlapping with Zealand Pharma's focus areas.
Novartis
NVS
Mkt Cap280.79B
Novartis is a global healthcare company that has a broad range of products competing in the diabetes and cardiovascular markets, overlapping with Zealand Pharma's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap119.87B
Bristol-Myers Squibb operates in multiple therapeutic areas including cardiovascular diseases, directly competing with some of Zealand Pharma's therapeutic development areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals competes with Zealand Pharma in the development of treatments for cardiovascular diseases, among other areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals is involved in creating transformative medicines for people with serious diseases, competing with Zealand Pharma's innovative approach to drug development.

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Show more...
CEO
Mr. Adam Sinding Steensberg M.D.
Employees
481
Country
Denmark
ISIN
DK0060257814
WKN
000A0YJW7

Listings

OTC Link
US
ZLDPY
F
DE
22Z1.F
STU
DE
22Z.STU
CO
DK
ZEAL.CO

0 Comments

Share your thoughts

FAQ

What is Zealand Pharma A/S. stock price today?▼
The current price of 22Z.F is €40.42 EUR — it has increased by +1.53% in the past 24 hours. Watch Zealand Pharma A/S. stock price performance more closely on the chart.
What is Zealand Pharma A/S. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zealand Pharma A/S. stocks are traded under the ticker 22Z.F.
Is Zealand Pharma A/S. stock price growing?▼
22Z.F stock has fallen by -2.56% compared to the previous week, the month change is a +5.95% rise, over the last year Zealand Pharma A/S. has showed a -29.88% decrease.
What is Zealand Pharma A/S. market cap?▼
Today Zealand Pharma A/S. has the market capitalization of 2.89B
When is the next Zealand Pharma A/S. earnings date?▼
Zealand Pharma A/S. is going to release the next earnings report on May 07, 2026.
What were Zealand Pharma A/S. earnings last quarter?▼
22Z.F earnings for the last quarter are -0.79 EUR per share, whereas the estimation was -1.07 EUR resulting in a +26.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Zealand Pharma A/S. revenue for the last year?▼
Zealand Pharma A/S. revenue for the last year amounts to 2.47B EUR.
What is Zealand Pharma A/S. net income for the last year?▼
22Z.F net income for the last year is 1.73B EUR.
How many employees does Zealand Pharma A/S. have?▼
As of April 29, 2026, the company has 481 employees.
In which sector is Zealand Pharma A/S. located?▼
Zealand Pharma A/S. operates in the Health & Wellness sector.
When did Zealand Pharma A/S. complete a stock split?▼
Zealand Pharma A/S. has not had any recent stock splits.
Where is Zealand Pharma A/S. headquartered?▼
Zealand Pharma A/S. is headquartered in Søborg, Denmark.